The global lixisenatide market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Lixisenatide is a once-daily injectable GLP-1 receptor agonist. It is sold under the brand name Lyxumia in the European Union and Adlyxin in the US. It is manufactured by Sanofi and is used to treat type 2 diabetes. The major factor driving the demand for lixisenatide is the increasing prevalence of diabetes across the globe.
According to the International Diabetes Federation (IDF), in 2021, approximately 537 million adults aged 20-79 years has diabetes globally with 3 in 4 adults with diabetes living in low- and middle-income countries with a mortality rate of 6.7 million people globally. Additionally, the total number of people living with diabetes is anticipated to rise to 643 million by 2030 and 783 million by 2045. Moreover, almost 1 in 2 (240 million) adults living with diabetes are undiagnosed. Hence, the rising prevalence of diabetes is encouraging the demand for lixisenatide.
To Request a Sample of our Report on Lixisenatide Market: https://www.omrglobal.com/request-sample/lixisenatide-market
Some major players in the market include Zealand Pharma A/S and Sanofi SA, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in October 2019, Sanofi announced the launch of Suliqua (insulin glargine/lixisenatide) in the UK. The drug is a once-daily, titratable, fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide used to treat type 2 diabetes in adults.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Product
- By Type of Manufacturing
- By End-User
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Zealand Pharma A/S, and Sanofi SA, among others.
(Get 15% Discount on Buying this Report)
A full Report of Lixisenatide Market is Available @ https://www.omrglobal.com/industry-reports/lixisenatide-market
Global Lixisenatide Market Report by Segment
By Product
- Industrial Grade
- Pharmaceutical Grade
By Type of Manufacturing
- In-house Manufacturing
- Contract Manufacturing Organizations
Global Lixisenatide Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
